As of January 22, 2025, Vanda Pharmaceuticals (VNDA) has a market cap of $0.26 billion USD. According to our data, Vanda Pharmaceuticals is ranked No.6862 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.26 B |
-8.66%
|
Dec 31, 2024 | $0.28 B |
13.51%
|
Dec 29, 2023 | $0.25 B |
-42.90%
|
Dec 30, 2022 | $0.43 B |
-52.90%
|
Dec 31, 2021 | $0.91 B |
19.41%
|
Dec 31, 2020 | $0.77 B |
-19.93%
|
Dec 31, 2019 | $0.96 B |
-37.20%
|
Dec 31, 2018 | $1.52 B |
71.91%
|
Dec 29, 2017 | $0.89 B |
-4.70%
|
Dec 30, 2016 | $0.93 B |
71.32%
|
Dec 31, 2015 | $0.54 B |
-34.99%
|
Dec 31, 2014 | $0.83 B |
15.39%
|
Dec 31, 2013 | $0.72 B |
235.41%
|
Dec 31, 2012 | $0.22 B |
-22.27%
|
Dec 30, 2011 | $0.28 B |
-49.68%
|
Dec 31, 2010 | $0.55 B |
-15.91%
|
Dec 31, 2009 | $0.66 B |
2,150.00%
|
Dec 31, 2008 | $29.15 M |
-92.73%
|
Dec 31, 2007 | $0.40 B |
-72.09%
|
Dec 29, 2006 | $1.44 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Jazz Pharmaceuticals
JAZZ
|
$7.31 B |
0.000 M
|
Ireland
|
Axsome Therapeutics
AXSM
|
$4.96 B |
0.000 M
|
USA
|
Intra-Cellular Therapies
ITCI
|
$13.51 B |
-0.000 M
|
USA
|
ACADIA Pharmaceuticals
ACAD
|
$2.96 B |
-0.000 M
|
USA
|
Biohaven Pharmaceutical
BHVN
|
$4.10 B |
-0.000 M
|
USA
|
Neurocrine Biosciences
NBIX
|
$14.86 B |
-0.000 M
|
USA
|
Sage Therapeutics
SAGE
|
$0.43 B |
-0.000 M
|
USA
|
Alkermes
ALKS
|
$4.89 B |
-0.000 M
|
Ireland
|
Corcept Therapeutics
CORT
|
$6.18 B |
0.000 M
|
USA
|
Supernus Pharmaceuticals
SUPN
|
$2.11 B |
-0.000 M
|
USA
|
Marinus Pharmaceuticals
MRNS
|
$30.13 M |
0.000 M
|
USA
|
Minerva Neurosciences
NERV
|
$15.31 M |
0.000 M
|
USA
|
Market Cap | = | VNDA Stock Price | * | VNDA Shares Outstanding |
= | $4.38 | * | 58.31 M | |
= | $0.26 B |